ArticleChild psychiatry and human development2025
Disease Burden of Autism Spectrum Disorder and Attention - Deficit/Hyperactivity Disorder in the 0-14 Age Group across 204 Countries and Regions from 1990 To 2021.
Article in Child psychiatry and human development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ropinirole adjunct to methylphenidate versus placebo adjunct to methylphenidate for attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial.European child & adolescent psychiatry · 2026Article
- Assortative Mating and Increase in Prevalence and Severity of Autistic Spectrum Disorder in Children-A Systematic Review.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to systematically analyze the disease burden of Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) in children aged 0-14 years, utilizing data from the Global Burden of Disease (GBD) 2021 database. By examining their temporal trends, regional distributions, and demographic differences, the study seeks to elucidate the epidemiological similarities and differences between the two disorders, thereby providing a scientific foundation for the development of prevention, diagnosis, and treatment strategies. This study, based on GBD 2021 data, analyzed the incidence, prevalence, and disability-adjusted life years (DALY) of ASD and ADHD globally from 1990 to 2021. The research employed age-standardized rates (ASR) to eliminate the influence of population age structure and explored the contributions of epidemiological changes, including population size, aging, as well as disease incidence, prevalence, mortality, and risk factors, to DALY through decomposition analysis. Additionally, the study performed an analysis of health inequalities, conducted a frontier analysis, and predicted future trends utilizing the Bayesian Age-Period-Cohort (BAPC) model. In 2021, the prevalence of ASD among the global population aged 0-14 years was 857.14 cases per 100,000 individuals (95% UI: 723.16-1009.04), while the prevalence of ADHD was 1,661.61 cases per 100,000 individuals (95% UI: 1,128.43-2,414.83). Within this age group, the DALY for ASD were 3,318,058 (95% UI: 2,248,324-4,668,010), compared to 410,705 (95% UI: 209,548-714,682) for ADHD. The DALY burden for ASD was higher than that for ADHD. These two disorders exhibit differences in gender and age distribution, with higher incidence rates and DALY values observed in males. Projections indicate that from 2021 to 2050, the DALY for both ASD and ADHD in the 0-14 age group are expected to show an upward trend.
Indexed as
Identifiers
40643744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.